AIM WINNERS & LOSERS: Sareum halts study over control group issues

Fri, 10th Oct 2025 10:10

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

----------

AIM - WINNERS

----------

Renalytix PLC, up 2.8% at 9.25 pence, 12-month range 5.75p-12.5p. The London-based precision diagnostics company has been notified by a Heights Capital Ireland LLC-advised fund that approximately USD4 million of non-amortising senior convertible bonds will be capitalised. Says 31.7 million ordinary shares will be issued to the Heights fund at 9.5p each, the same in Renalytix's recent fundraise, which raised just over GBP1.0 million via subscription by ABRDN World Healthcare Fund for 11 million shares. Renalytix says the bond conversion will improve its debt-to-equity ratio and significantly improve its balance sheet, improving its net asset position by around USD4 million and saving up to USD1.4 million in accrued interest over the remaining life of the loan. Expects the conversion shares to be admitted to trading on Wednesday.

----------

AIM - LOSERS

----------

Sareum Holdings PLC, down 22% at 15.5p, 12-month range 11.25p-31p. The Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors for autoimmune disease and cancer, has discontinued its 16-week GLP preclinical toxicology study for SDC-1801, following safety findings observed by the study's third-party provider. Says the safety issues showed a higher incidence in the control group animals, which were given an inactive dosing solution, compared to the animals dosed with SDC-1801, according to a preliminary assessment. The study, which was designed to support longer-term dosing of SDC-1801 and investigate its toxicology, will be formally closed once scheduled analyses and reporting activities are completed. However, due to the disproportionate amount of the safety issues being in the control group, Sareum says the issues are considered highly unlikely to be related to SDC-1801. Says it is reviewing the study data with the contractor and expert consultants, to determine the cause and the next steps, and that it is in talks with alternative providers with the intention of restarting the study as soon as possible. "Despite this setback, the company anticipates being able to complete the full toxicology study, as originally scoped, with its existing cash resources," it says.

----------

Dekel Agri-Vision PLC, down 19% at 0.425p, 12-month range 0.425p-1.625p. The West Africa-focused agricultural company reports crude palm oil production of 2,727 tonnes in the third quarter, down 49% compared to the year before. CPO extraction remains stable at 19.4%, while CPO sales volume falls 58% although all CPO output for the quarter was sold. Sales price increased 24% to EUR964 per tonne. The palm kernel oil sales price rose 47%. Dekel says its cashew operation has shown substantial improvement in recent months and is now consistently processing over 500 tonnes of raw cashew nuts per month. Aims to achieve a monthly run rate of over 700 tonnes by the end of next year.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com